JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Effects of TNFalpha, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Effects of TNFalpha, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases
Basmaci, C; Pehlivan, M; Tomatir, AG; Sever, T; Okan, V; Yilmaz, M; Oguzkan-Balci, S; Pehlivan, S;
  PDF(new window)
 Abstract
It is not clear how gene polymorphisms affecting drugs can contributes totheir efficacy in multiple myeloma (MM). We here aimed to explore associations among gene polymorphisms of tumor necrosis factor alpha (TNFalpha), nitric oxide synthesis 3 (NOS3) and multi-drug resistance 1 (MDR1), clinical parameters, prognosis and survival in MM patients treated with VAD (vincristine-adriamycine-dexamethasone), MP (mephalane-prednisolone), autolougus stem cell transplantation (ASCT), BODEC (bortezomib-dexamethasone-cyclophosphamide) and TD (thalidomide-dexamethasone). We analyzed TNFalpha, NOS 3 and MDR1 in 77 patients with MM and 77 healthy controls. The genotyping was performed with PCR and/or PCR-RFLP. There was no clinically significant difference between MM and control groups when TNFalpha (-238) and (-857) and MDR1 gene polymorphisms were studied. However, the TNFalpha gene polymorphism (-308) GG genotype (p
 Keywords
Multiple myeloma;NOS3 (+894, VNTR);TNFalpha (-308, -238 and -857);MDR1;
 Language
English
 Cited by
1.
The Genes of Life and Death: A Potential Role for Placental-Specific Genes in Cancer, BioEssays, 2017, 39, 11, 1700091  crossref(new windwow)
 References
1.
Akcali A, Pehlivan S, Pehlivan M, et al (2010). TNF-alpha promoter polymorphisms in multiple sclerosis: no association with -308 and -238 alleles, but the -857 alleles in associated with the disease in Turkish patients. Int J Immunogenet, 37, 91-5. crossref(new window)

2.
Banu C, Moise A, Arion CV, et al (2011). Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients. J Med Life, 4, 264-8.

3.
Bivalacqua TJ, Champion HC, Hellstrom WJG (2002). Implications of nitric oxide synthases isoforms in the pathophysiology of Peyronie’s disease. Int J Imp Res, 14, 345-2. crossref(new window)

4.
Black RA, Rauch CT, Kozlosky CJ, et al (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 385, 729-33. crossref(new window)

5.
Buda G, Maggini V, Galimberti S, et al (2007). MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol. 137, 454-6. crossref(new window)

6.
Buda G, Ricci D, Huang CC, et al (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 89, 1133-40. crossref(new window)

7.
Cox DR (1972). Regression models and life-tables. J R Stat Soc Ser B, 34, 187-220.

8.
Dogra S, Khullar G (2013). Tumor necrosis factor-${\alpha}$ antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol, 7, 35-46.

9.
Drain S, Catherwood MA, Orr N, et al (2009). ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma, 50, 566-570. crossref(new window)

10.
Du J, Yuan ZG, Zhang CY, et al (2009). Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma. Zhonghau Xue Ye Xeu Za Zhi, 30, 649-53.

11.
Game X, Rischmann P, Arnal JF, et al (2013). Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role]. Prog Urol, 23, 926-35. crossref(new window)

12.
Germann, UA (1996). P-glycoprotein--a mediator of multidrug resistance in tumour cells. Eur J Cancer. 32, 927-44. crossref(new window)

13.
Ghilardi G, Biondi ML, Cecchini F, et al (2003). Vasculer invasion in human breast cancer is coralated to T->786C polymophism of NOS3 gene. Nitric Oxide, 9, 118-22. crossref(new window)

14.
Hefler LA, Grimm C, Lantzsch T, et al (2006). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat, 98, 151-55. crossref(new window)

15.
Hefler LA, Ludwig E, Lampe D, et al (2002). Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol, 86,134-37. crossref(new window)

16.
Heil M, Eitenmuller I, Schmitz-Rixen T, et al (2006). Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med, 10, 45-55. crossref(new window)

17.
Ichimaru M, Ishimaru T, Mikami M, et al (1982). Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: Relationship to radiation dose absorbed by marrow. J Natl Cancer Inst, 69, 323-28.

18.
Iokupova EV, Grinchuk OV, Kalimullina DKh, et al (2003). Molecular genetic analysis of the IL-6 and Tumor necrosis factor alpha gene polymorphisms in multiple myeloma. Mol Biol (Mosk), 37, 420-24.

19.
Jamroziak K, Balcerczak E, Cebula B, et al (2005). Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep, 57, 882-8.

20.
Juliano RL, Ling VA (1976). Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152-62. crossref(new window)

21.
Kadar K, Kovacs M, Karadi I, et al (2008). Polymorphism of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 32, 1499-504. crossref(new window)

22.
Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81. crossref(new window)

23.
Knop S (2014). The multiple myeloma - current view and perspectives. Med Monatsshr Pharm, 37, 84-92.

24.
Kyle RA (1994). Multiple myeloma: How did it begin? Mayo Clin Proc, 69, 680-83. crossref(new window)

25.
Medeiros R, Morais A, Vasconcelos A, et al (2002). Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev, 11, 343-50. crossref(new window)

26.
Nakamura K, Matsuzawa N, Ohmori S, et al (2013). Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy. Drug Metab Pharmacokinet, 28, 38-43. crossref(new window)

27.
Nathan C, Xie QW (1994). Nitric oxide synthases. Roles, tolls and controls. Cell, 78, 915-8. crossref(new window)

28.
Neben K, Mytilineos J, Moehler TM, et al (2002). Polymorphisms of the tumor necrosis factor-${\alpha}$ gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 100, 2263-65.

29.
Olmos G, Llado J (2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm, 2014, 861231.

30.
Riener EK, Hefler LA, Grimm C, et al (2004). Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecol Oncol, 93, 686-90. crossref(new window)

31.
Wajant H, Pfizenmaier K, Scheurich P (2003). Tumor necrosis factor signaling. Cell Death Differ, 10, 45-65. crossref(new window)

32.
Wang SS, Davis S, Cerhan JR, et al (2006). Polymorphisims in oxidative stres genes and risk for non-Hodgkin lymphoma. Carcinogenesis, 27, 1828-34. crossref(new window)